1
FDA Pauses PepGen’s DMD Drug Trial in the US
Kelsey Hales edited this page 1 week ago
The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind, Check this out placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US, such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 trial in the US by end of year. PepGen did not mention a specific reason for the decision